Declines in Alector's stock valuation are frequently driven by clinical trial setbacks, pipeline restructuring, or broader investor risk aversion toward clinical-stage biotechnology companies. For instance, announcements regarding the discontinuation of major phase trials following interim futility analyses—such as decisions concerning its Alzheimer's disease programs—tend to heavily impact market confidence. Additionally, reductions in collaboration revenues and broader market shifts away from pre-revenue biotech equities often exert downward momentum on the stock.